Harnessing the City’s financial firepower for UK life sciences: a panel discussion with George Freeman MP
UK life sciences goes from strength to strength, but financing available for the sector still lags behind that available across the Atlantic. At JP Morgan, the Prime Minister committed to change this by deploying the financial firepower of the City of London behind UK life sciences. At this event, we will discuss how this can be achieved with his Science Minister George Freeman MP and financial and industry experts. We will ask if and how the UK can build a holistic financing ecosystem, as see in Boston Massachusetts, by developing and attracting talent, replicating innovative investment vehicles and stimulating greater participation from institutional investors, such as pension funds. The BIA will also launch its latest analysis of UK biotech and life sciences sector investment activity in 2021. Copies will be available at the event.
Join us for the panel discussion followed by networking with refreshments. There will be space at the venue before the event to meet informally with others and grab a coffee. Changing areas will also be made available for those going on to the Gala Dinner nearby.
This event is open to BIA members, gala dinner attendees and investors.
15.30 Registration opens, networking & refreshments
16.25 Welcome from Steve Bates, CEO, BIA
16.30 Panel session chaired by Martin Turner, Head of Policy and Public Affairs, BIA
- George Freeman MP, Science Minister
- Clare Terlouw, Head of LifeArc Ventures, LifeArc
- Dr Allan Marchington, Managing Director, Life Sciences, Intermediate Capital Group
- Steve Aherne, Partner, PwC
17.45 Drinks reception
18.45 Event closes
This event is open to BIA members, gala dinner attendees and investors.
To book, please email the below information to Samantha Care at firstname.lastname@example.org
- Full name
- Job title
- Any dietary requirements
Stephen is a Partner within the PwC Valuation and Strategy practice and leads the Pharmaceutical and Healthcare valuation offering.
He has over 14 years of experience within PwC, including 13 years specialising in the pharmaceutical and healthcare sectors.
Stephen has provided industry specific valuation advice for mergers and acquisitions, financial reporting, expert opinions, corporate restructuring and refinancing purposes. He regularly conducts both business valuations and intellectual property valuations such as licences, patents and trademarks. He has also led strategy projects and market analysis for pharmaceutical and healthcare clients.
His clients include large and medium pharmaceutical, medical technology, biotechnology and both public and private healthcare companies.
He presents externally on valuations in the pharmaceutical sector, for example at the Association of British Pharmaceutical Industry Intellectual Property Seminar on “Valuing your IP Assets”.
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
George Freeman is Parliamentary Under Secretary of State (Minister for Science, Research and Innovation).
Elected to Parliament in 2010 after a 15-year career founding high-growth technology companies. George has served in the last three Governments as UK Trade Envoy, the first UK Minister for Life Science, Chair of the No10 Policy Board and Minister of State at the Department for Transport.
Most recently, he led the Prime Minister’s Task Force on Innovation, Growth and Regulatory Reform (TIGRR).
He is Founder of the Big Tent Festival and Foundation, the Reform for Resilience Global Health Commission and the 2020 Conservatives Group. He is also author of Britain Beyond Brexit and the former Chair of the Conservative Policy Forum.
Allan joined ICG in January 2021 and is Managing Director, and Head of Life Sciences, responsible for the Life Science Fund strategy and team at ICG.
Prior to ICG, Allan was Founder and Managing Partner of Bridge Valley Ventures, a successful life science investor, and prior to this was a Partner and Founder of Apposite Capital. Before this Allan was at Abingworth.
Formerly a PhD medicinal chemist at Pfizer, he later founded and was CEO of his own life sciences company before it was successfully acquired by Millennium Pharmaceuticals Inc. in 2000 where he became SVP Technology. On his return to the UK in 2003 Allan joined Abingworth to begin his investment career.
Clare Terlouw is Head of LifeArc Ventures, responsible for LifeArc’s investments across the life science sector.
She is the head of the investment team and a member of the Early Ventures Investment Committee. Clare oversees the Early Ventures strategy at LifeArc, which is a seed to Series A investment strategy, with the ability to further fund select companies into later rounds of funding. LifeArc’s investment strategy is to seek to generate positive impact on patients and financial returns by investing in early translational sciences and technologies in areas of high unmet patient need.
Clare was previously at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust, where she was Head of Corporate Development. Syncona founds and builds life sciences companies to deliver transformational treatments to patients. She has 15 years of biotech and healthcare financing experience as an investment banker in the City of London, previously a Managing Director at Numis Securities, with significant expertise in growth funding for innovative life sciences companies in the private and public markets.
Clare is also a board member of the BioIndustry Association, a non-executive director of Stevenage Bioscience Catalyst, and an investor director on a number of private venture backed companies.
Martin is responsible for the BIA's policy outputs and public affairs activities, and leads on finance and tax policy and the BIA’s engagement with the investment community. He also provides the secretariat for the BIA’s Finance and Tax Advisory Committee.
Martin has over ten years’ experience in policy and public affairs and has worked at the Royal Society, the Campaign for Science and Engineering, and the Association of Medical Research Charities. Before embarking on a career in policy, Martin completed a PhD in molecular biology at the University of Sheffield, where he also co-founded and was director of an award-winning science communication charity called Science Brainwaves. He has a BSc in molecular biology from the University of Manchester.